Key upcoming clinical catalysts for biotech
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Finding the next Prevail
An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.
Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Ash 2020 – Forma gets an early edge over Agios in sickle cell disease
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Bluebird’s early-stage sickle cell gene therapy shows promise
Crispr Therapeutics might have stolen the Ash headlines, but a similar approach from Bluebird is also making progress.
Ash 2020 – Crispr gets another boost
Data in three more patients support Crispr and Vertex’s hope of developing a functional cure for beta-thalassaemia and sickle cell disease.
Ash 2020 preview – late-breaker puts Uniqure in pole position
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
